Welcome to our dedicated page for Evogene SEC filings (Ticker: EVGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Evogene鈥檚 multi-subsidiary disclosures can feel overwhelming; a single 10-K packs gene-editing breakthroughs, microbiome trial results, and castor-seed revenue into more than 300 pages. That鈥檚 why Stock Titan offers Evogene SEC filings explained simply. Whether you need the science behind MicroBoost AI or the cash burn of Biomica, our AI highlights the essentials and drops you at the exact section鈥攏o manual scrolling.
Ask natural questions like 鈥淲here can I find the Evogene quarterly earnings report 10-Q filing?鈥� or 鈥淭rack Evogene insider trading Form 4 transactions.鈥� Our platform answers in plain English and links directly to each document. AG真人官方-time feeds push Evogene Form 4 insider transactions real-time to your dashboard, while instant cards titled 鈥�Evogene 8-K material events explained鈥� flag every development. Built-in analytics surface R&D spend shifts and segment margins, turning raw text into insight faster than you can open EDGAR.
For deeper research, dive into the Evogene annual report 10-K simplified to uncover revenue by tech-engine, or open the Evogene proxy statement executive compensation to review option grants and board pay. AI-curated dashboards show Evogene executive stock transactions Form 4 alongside price performance, giving context to buying or selling. Whether you鈥檙e understanding Evogene SEC documents with AI or seeking Evogene earnings report filing analysis for your model, Stock Titan converts complex biotech filings into immediate clarity.
Evogene Ltd. (EVGN) 鈥� Form 6-K filed 8 July 2025
The filing reports that subsidiary Lavie Bio Ltd. has closed its previously announced transaction with Dead Sea Works Ltd. (ICL Group affiliate), transferring 鈥渕ost of the activity鈥� of Lavie Bio to ICL. The company attaches a press release (Exhibit 99.1) for additional information, but no financial terms, consideration amounts, or post-deal collaboration details are disclosed in the body of the 6-K.
Strategically, completion of the sale marks a significant portfolio shift for Evogene, whose computational biology platform has used Lavie Bio as a commercialization channel for ag-biological products. Divestiture may provide fresh capital and external validation while allowing management to redeploy resources toward other growth engines; however, absent numerical data investors cannot yet evaluate the deal鈥檚 effect on liquidity, earnings trajectory, or future royalty streams.
The 6-K contains no updates to revenue guidance, balance-sheet figures, or operational outlook. The document is automatically incorporated into Evogene鈥檚 effective Form F-3 and Form S-8 registration statements cited in the filing.
FAQ
What is the current stock price of Evogene (EVGN)?
What is the market cap of Evogene (EVGN)?
What is Evogene's core business?
What proprietary technologies does Evogene use?
How does Evogene contribute to agricultural productivity?
What are Evogene's main market segments?
Who are Evogene's key subsidiaries?
How does Evogene's technology reduce development time and cost?
What differentiates Evogene from other biotech companies?
How does Evogene maintain its competitive edge in the industry?
